- ►diabetesjournals.org H Kim, M Haluzik, Z Asghar, D Yau, JW Joseph, AM … - Diabetes, 2003 - Am Diabetes Assoc Abnormalities in insulin action are the characteristics of type 2 diabetes. Dominant-negative
muscle-specific IGF-I receptor (MKR) mice exhibit elevated lipid levels at an early age and eventually
develop type 2 diabetes. To evaluate the role of elevated lipids in the progression of the ... Cited by 110 - Related articles - BL Direct - All 4 versions
CJ Chou, M Haluzik, C Gregory, KR Dietz, C Vinson … - Journal of Biological …, 2002 - ASBMB WY14,643 is a specific peroxisome proliferator-activated receptor α (PPARα) agonist with strong
hypolipidemic effects. Here we have examined the effect of WY14,643 in the A-ZIP/F-1
mouse, a model of severe lipoatrophic diabetes. With 1 week of treatment, all doses of ... Cited by 103 - Related articles - BL Direct - All 4 versions
EH Koh, MS Kim, JY Park, HS Kim, JY Youn, HS Park, … - Diabetes, 2003 - Am Diabetes Assoc Lipid accumulation in nonadipose tissues is closely related to the development of type 2 diabetes
in obese subjects. We examined the potential preventive effect of peroxisome proliferator-activated
receptor (PPAR)-α and PPAR-γ stimulation on the development of diabetes in obese ... Cited by 104 - Related articles - BL Direct - All 6 versions
JM Ye, PJ Doyle, MA Iglesias, DG Watson, GJ Cooney, … - Diabetes, 2001 - Am Diabetes Assoc Peroxisome proliferator—activated receptor (PPAR)-α agonists lower circulating lipids, but the
consequences for muscle lipid metabolism and insulin sensitivity are not clear. We investigated
whether PPAR-α activation improves insulin sensitivity in insulin-resistant rats and ... Cited by 240 - Related articles - BL Direct - All 6 versions
M Guerre-Millo, P Gervois, E Raspe, L Madsen, P … - Journal of Biological …, 2000 - ASBMB Fibrates and glitazones are two classes of drugs currently used in the treatment of dyslipidemia
and insulin resistance (IR), respectively. Whereas glitazones are insulin sensitizers acting via
activation of the peroxisome proliferator-activated receptor (PPAR) subtype, fibrates exert ... Cited by 382 - Related articles - BL Direct - All 5 versions
M Guerre-Millo, C Rouault, P Poulain, J André, V … - Diabetes, 2001 - Am Diabetes Assoc Peroxisome proliferator–activated receptor (PPAR)-α controls the expression of genes involved
in lipid metabolism. PPAR-α furthermore participates to maintain blood glucose during acute
metabolic stress, as shown in PPAR-α–null mice, which develop severe hypoglycemia ... Cited by 136 - Related articles - BL Direct - All 6 versions
RHJ Bandsma, TH van Dijk, A Harmsel, T Kok, DJ … - Journal of Biological …, 2004 - ASBMB Apart from impaired -oxidation, Ppar -deficient (Ppar –/– ) mice suffer from hypoglycemia during
prolonged fasting, suggesting alterations in hepatic glucose metabolism. We compared hepatic
glucose metabolism in vivo in wild type (WT) and Ppar –/– mice after a short term fast, ... Cited by 27 - Related articles - BL Direct - All 5 versions
JN MacLeod, BH Shapiro - Laboratory animal science, 1988 - ncbi.nlm.nih.gov A re-usable mobile catheterization apparatus was developed that permits multiple blood samples
to be obtained from nonrestrained and unanesthetized mice. The collection end of the catheter
is located outside the cage allowing the mouse to remain completely undisturbed prior to ... Cited by 33 - Related articles - All 2 versions
[CITATION] WY14, 643, a peroxisome proliferator-activated receptor(PPAR) agonist, improves …
- ►endojournals.org K Ravnskjaer, M Boergesen, B Rubi, JK Larsen, T … - Endocrinology, 2005 - Endocrine Soc Fatty acids (FAs) are known to be important regulators of insulin secretion from pancreatic
ß-cells. FA-coenzyme A esters have been shown to directly stimulate the secretion process, whereas
long-term exposure of ß-cells to FAs compromises glucose-stimulated insulin secretion ( ... Cited by 45 - Related articles - BL Direct - All 2 versions
